MedDataX Logo

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

NCT ID: NCT06016556

Last Updated: 2025-06-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-17

Study Completion Date

2024-04-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

NCT05263908

SARS-CoV-2 Infection
COMPLETED

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

NCT05438602

COVID-19
COMPLETED PHASE2

A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.

NCT07261085

COVID-19
ACTIVE_NOT_RECRUITING

Favipiravir Therapy in Adults With Mild COVID-19

NCT04464408

COVID-19
COMPLETED PHASE2/PHASE3

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091

Long COVID
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)

Adult COVID-19 patients' HCRU within the 30-day period following nirmatrelvir, ritonavir prescription.

nirmatrelvir, ritonavir

Intervention Type DRUG

single cohort

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nirmatrelvir, ritonavir

single cohort

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paxlovid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed COVID-19 infection during the study observation period
* Nirmatrelvir, ritonavir written prescription

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

King Faisal Specialist Hospital & research center - Jeddah

Jeddah, , Saudi Arabia

Site Status

King Abdulaziz Medical City

Riyadh, , Saudi Arabia

Site Status

King Faisal Specialist Hospital and Research Center

Riyadh, , Saudi Arabia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=C4671054

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCT06016556

Identifier Type: REGISTRY

Identifier Source: secondary_id

C4671054

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco
NCT05997485 WITHDRAWN
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
NCT05545319 WITHDRAWN PHASE2
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
NCT07089680 NOT_YET_RECRUITING
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
NCT04847622 COMPLETED
Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
NCT04694612 UNKNOWN PHASE3
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
NCT05567952 COMPLETED PHASE2
Effectiveness and Safety of New Oral Antivirals for COVID-19
NCT05894603 UNKNOWN
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
NCT05965726 COMPLETED PHASE2
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
NCT05387369 RECRUITING
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
NCT04358549 COMPLETED PHASE2
Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease
NCT05938140 UNKNOWN PHASE4
To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
NCT05369676 COMPLETED PHASE1/PHASE2
Defibrotide for the Treatment of Severe COVID-19
NCT04652115 RECRUITING PHASE2
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
NCT05487040 TERMINATED PHASE1
ImPROving Quality of LIFe in the Long COVID Patient
NCT05823896 COMPLETED PHASE2
Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study
NCT05532852 UNKNOWN NA
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
NCT07090486 COMPLETED
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
NCT04745351 TERMINATED PHASE3
Favipiravir in High-risk COVID-19 Patients
NCT04818320 COMPLETED PHASE3
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
NCT05047601 COMPLETED PHASE2/PHASE3
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
NCT04336904 UNKNOWN PHASE3
Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients
NCT05749445 UNKNOWN
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
NCT05386472 TERMINATED PHASE1
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
NCT04960202 COMPLETED PHASE2/PHASE3
A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19
NCT05890612 RECRUITING